Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6SFYH)

Drug Name
[14C]TEA Drug Info
Synonyms
Tetraethylammonium; Tetrylammonium; TETRAETHYLAMMONIUM ION; Tetramon; tetraethylazanium; N,N,N-Triethylethanaminium; tetraethylamine; UNII-5AV7G7EIEE; Tetraetilammonio [Italian]; 66-40-0; 5AV7G7EIEE; BRN 1738225; CHEMBL9324; AMMONIUM, TETRAETHYL-; CHEBI:44296; C8H20N; Tetraetilammonio; [14C]-TEA; tetraethyl ammonium; AC1L1KAW; Lopac-T-2265; 77-98-5 (hydroxide); 71-91-0 (bromide); 56-34-8 (chloride); 68-05-3 (iodide); SCHEMBL16267; 4-04-00-00331 (Beilstein Handbook Reference); NEt4(+); GTPL4575; GTPL2343; Ethanaminium,; [14C]-TEA ; tetraethylammonium
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5413
ChEBI ID
CHEBI:44296
CAS Number
CAS 66-40-0
TTD Drug ID
DM6SFYH
VARIDT Drug ID
DR00106

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Calcium-activated potassium channel KCa4.1 (KCNT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
phorbol 12-myristate 13-acetate DMJWD62 Acute myeloid leukaemia 2A60 Phase 2 [5]
iberiotoxin DMRIG3O Discovery agent N.A. Investigative [38]
Drug(s) Targeting Calcium-activated potassium channel KCa2.3 (KCNN3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
dequalinium DMXM19W Myelopathy 8B42 Clinical trial [39]
EBIO DMPKI0N Discovery agent N.A. Investigative [3]
UCL1684 DMZNJFU Discovery agent N.A. Investigative [40]
DC-EBIO DM2T5OV Discovery agent N.A. Investigative [41]
UCL1848 DM2CN0A Discovery agent N.A. Investigative [40]
apamin DMYNBK5 Discovery agent N.A. Investigative [40]
CyPPA DM64L9I Discovery agent N.A. Investigative [42]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Inward rectifier potassium channel Kir2.3 (KCNJ4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
rose bengal (photoactivated) DM3NBQ6 Discovery agent N.A. Investigative [43]
Drug(s) Targeting Calcium-activated potassium channel KCa2.1 (KCNN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
dequalinium DMXM19W Myelopathy 8B42 Clinical trial [44]
EBIO DMPKI0N Discovery agent N.A. Investigative [3]
UCL1684 DMZNJFU Discovery agent N.A. Investigative [3]
UCL1848 DM2CN0A Discovery agent N.A. Investigative [45]
apamin DMYNBK5 Discovery agent N.A. Investigative [44]
Drug(s) Targeting Voltage-gated potassium channel Kv1.5 (KCNA5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dronedarone DMA8FS5 Angina pectoris BA40 Approved [46]
BMS-919373 DMN28WK Atrial fibrillation BC81.3 Phase 2 [47]
IQB-9302 DMET0H4 Pain MG30-MG3Z Phase 1 [48]
XEN-D0103 DMR0U4V Atrial fibrillation BC81.3 Phase 1 [49]
BMS-394136 DMGDJQR Arrhythmia BC9Z Phase 1 [50]
XEN-D0101 DMU0V45 Atrial fibrillation BC81.3 Phase 1 [51]
T-226296 DMJ6P9U Obesity 5B81 Preclinical [46]
Zatebradine DMNYKOT Angina pectoris BA40 Terminated [52]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L Discovery agent N.A. Investigative [53]
clofilium DMQ37OP Discovery agent N.A. Investigative [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv1.2 (KCNA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
mast cell degranulating peptide DMDZIHT Discovery agent N.A. Investigative [12]
Drug(s) Targeting Voltage-gated potassium channel Kv3.4 (KCNC4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DABCO-C16 DMN3GTF Discovery agent N.A. Investigative [55]
DABCO DMHZKMG Discovery agent N.A. Investigative [55]
Drug(s) Targeting Calcium-activated potassium channel KCa5.1 (KCNU1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
iberiotoxin DMRIG3O Discovery agent N.A. Investigative [56]
Drug(s) Targeting Solute carrier family 47 member 1 (SLC47A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metformin DM89QE1 Colorectal carcinoma Approved [10]
Drug(s) Targeting Aquaporin-1 (AQP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AAV-AQP1 DMI27RF Xerostomia DA02.1 Phase 1/2 [57]
Drug(s) Targeting Voltage-gated potassium channel Kv2.1 (KCNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DABCO-C16 DMN3GTF Discovery agent N.A. Investigative [55]
RY796 DMW4850 Discovery agent N.A. Investigative [58]
3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol DMZ8WMA Discovery agent N.A. Investigative [59]
Drug(s) Targeting Voltage-gated potassium channel Kv3.1 (KCNC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
norfluoxetine DMKNUP3 Discovery agent N.A. Investigative [60]
Drug(s) Targeting Voltage-gated potassium channel Kv7.3 (KCNQ3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Retigabine DMGNYIH Behcet disease 4A62 Approved [61]
Linopirdine DM0ZOGX Cognitive impairment 6D71 Phase 3 [62]
ICA-105665 DMP925B Epilepsy 8A60-8A68 Phase 2 [63]
XEN1101 DMJVL57 Epilepsy 8A60-8A68 Phase 1 [64]
ICA-69673 DM1RZVI Pain MG30-MG3Z Preclinical [65]
PD-32577 DMBA15J Discovery agent N.A. Investigative [66]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv7.5 (KCNQ5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
zinc pyrithione DMF0CRA Discovery agent N.A. Investigative [67]
XE991 DMLH1PK Discovery agent N.A. Investigative [25]
(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide DMGFOQJ Discovery agent N.A. Investigative [68]
Drug(s) Targeting Voltage-gated potassium channel Kv7.4 (KCNQ4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PIP2 DMOZV7N Discovery agent N.A. Investigative [69]
zinc pyrithione DMF0CRA Discovery agent N.A. Investigative [67]
XE991 DMLH1PK Discovery agent N.A. Investigative [70]
(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide DMGFOQJ Discovery agent N.A. Investigative [68]
NC00075159 DMJCYMW Discovery agent N.A. Investigative [71]
ML213 DMFAUGP Discovery agent N.A. Investigative [72]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv1.6 (KCNA6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
mast cell degranulating peptide DMDZIHT Discovery agent N.A. Investigative [13]
Drug(s) Targeting Voltage-gated potassium channel Kv2.2 (KCNB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RY796 DMW4850 Discovery agent N.A. Investigative [58]
Drug(s) Targeting Charybdotoxin receptor beta-4 (BKbeta4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-223131 DMJUV6C Erectile dysfunction HA01.1 Phase 2 [73]
NS-1619 DMES0OT Asthma CA23 Terminated [74]
CNS-1237 DMP3QAZ Cerebrovascular ischaemia 8B1Z Terminated [75]
iberiotoxin DMRIG3O Discovery agent N.A. Investigative [7]
paxilline DMPF2N1 Discovery agent N.A. Investigative [76]
slotoxin DMBD6TC Discovery agent N.A. Investigative [77]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv7.2 (KCNQ2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ICA-69673 DM1RZVI Pain MG30-MG3Z Preclinical [65]
PIP2 DMOZV7N Discovery agent N.A. Investigative [69]
PD-32577 DMBA15J Discovery agent N.A. Investigative [66]
zinc pyrithione DMF0CRA Discovery agent N.A. Investigative [67]
XE991 DMLH1PK Discovery agent N.A. Investigative [78]
(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide DMGFOQJ Discovery agent N.A. Investigative [68]
QO-58 DMYXPF8 Discovery agent N.A. Investigative [79]
ICA-27243 DMO0N3Q Discovery agent N.A. Investigative [80]
ztz240 DM60N3C Discovery agent N.A. Investigative [81]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv1.3 (KCNA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Debio-0824 DMV401D Psoriasis vulgaris EA90 Phase 1b/2a [82]
Dalazatide DMJ1NG4 Inclusion body myositis 4A41.2 Phase 1b/2a [83]
UK-78282 DMKBILF Inflammation 1A00-CA43.1 Terminated [84]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L Discovery agent N.A. Investigative [85]
2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide DM31E6J Discovery agent N.A. Investigative [86]
correolide DMACH7K Discovery agent N.A. Investigative [87]
Correloid DM5ISQK Discovery agent N.A. Investigative [88]
CP-339818 DMTJOWH Discovery agent N.A. Investigative [84]
5-(4-Phenylbutoxy)psoralen DM3QFCV Discovery agent N.A. Investigative [89]
[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine DMH3BG5 Discovery agent N.A. Investigative [90]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Calcium-activated potassium channel KCa4.2 (KCNT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
phorbol 12-myristate 13-acetate DMJWD62 Acute myeloid leukaemia 2A60 Phase 2 [5]
iberiotoxin DMRIG3O Discovery agent N.A. Investigative [91]
Drug(s) Targeting Transient receptor potential cation channel V2 (TRPV2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-APB DM9AKVR Discovery agent N.A. Investigative [11]
lysophosphatidylcholine DMOGFVH Discovery agent N.A. Investigative [92]
diphenylboronic anhydride DMRQZTS Discovery agent N.A. Investigative [11]
lysophosphatidylinositol DMETM3R Discovery agent N.A. Investigative [92]
citral DM53ZGY Discovery agent N.A. Investigative [93]
cannabinol DMM6A7P Discovery agent N.A. Investigative [94]
TRIM DMNHU4M Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv1.7 (KCNA7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
tedisamil DM0HJD4 Discovery agent N.A. Investigative [95]
Drug(s) Targeting Voltage-gated potassium channel Kv1.1 (KCNA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
mast cell degranulating peptide DMDZIHT Discovery agent N.A. Investigative [12]
Drug(s) Targeting Calcium-activated potassium channel KCa2.2 (KCNN2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
dequalinium DMXM19W Myelopathy 8B42 Clinical trial [96]
zoxazolamine DM70TKB Multiple myeloma 2A83 Terminated [97]
EBIO DMPKI0N Discovery agent N.A. Investigative [3]
UCL1684 DMZNJFU Discovery agent N.A. Investigative [44]
DC-EBIO DM2T5OV Discovery agent N.A. Investigative [98]
UCL1848 DM2CN0A Discovery agent N.A. Investigative [99]
apamin DMYNBK5 Discovery agent N.A. Investigative [100]
CyPPA DM64L9I Discovery agent N.A. Investigative [42]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Transported By Organic cation transporter 2 (SLC22A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [101]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [102]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [103]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [104]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [105]
Propranolol DM79NTF Angina pectoris BA40 Approved [106]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [107]
Metformin DM89QE1 Colorectal carcinoma Approved [108]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [106]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [109]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Multidrug and toxin extrusion protein 1 (SLC47A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aciclovir DMYLOVR Genital herpes 1A94 Approved [28]
Metformin DM89QE1 Colorectal carcinoma Approved [110]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [28]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [28]
Chloroquine DMSI5CB Malaria 1F40-1F45 Approved [111]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [28]
Topotecan DMP6G8T Central nervous system neoplasm Approved [28]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [112]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [113]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [114]
Pyrimethamine DM5X7VY Malaria 1F40-1F45 Approved [145]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [146]
Verapamil DMA7PEW Angina pectoris BA40 Approved [147]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [146]
Methotrexate DM2TEOL Anterior urethra cancer Approved [148]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [149]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [133]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [150]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [135]
Quinidine DMLPICK N. A. N. A. Approved [146]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Transported By Organic cation transporter 1 (SLC22A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [101]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [115]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [116]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [117]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [118]
Verapamil DMA7PEW Angina pectoris BA40 Approved [119]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [120]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [121]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [122]
Propranolol DM79NTF Angina pectoris BA40 Approved [106]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Multidrug and toxin extrusion protein 2 (SLC47A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aciclovir DMYLOVR Genital herpes 1A94 Approved [28]
Metformin DM89QE1 Colorectal carcinoma Approved [28]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [28]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [28]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [28]
Topotecan DMP6G8T Central nervous system neoplasm Approved [28]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [113]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [114]
Estrone sulfate DMVBIZL Atrophic vaginitis GA30.2 Approved [28]
N-methylpyridinium DMVUKEW N. A. N. A. Preclinical [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic cation/carnitine transporter 1 (SLC22A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [123]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [123]
Cytarabine DMZD5QR Acute lymphoblastic leukaemia 2A85 Approved [124]
Levacecarnine hci DMJBOCR Cognitive impairment 6D71 Approved [125]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [126]
Ipratropium DMFQ320 Obstructive lung disease CA22.Z Approved [127]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Affected By Solute carrier family 22 member 4 (SLC22A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Levacecarnine hci DMJBOCR Cognitive impairment 6D71 Approved [128]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [129]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [130]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [131]
Leflunomide DMR8ONJ Arthritis FA20 Approved [132]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [133]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [134]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [135]
Sodium lauryl sulfate DMLJ634 Constipation DD91.1 Approved [136]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [137]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 22 member 2 (SLC22A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [138]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [139]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [139]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [109]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [140]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [109]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [141]
Trospium chloride DM32XZT Discovery agent N.A. Approved [142]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [143]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [144]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily A member 1 (KCNA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [151]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [134]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [152]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [153]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [154]
Trichostatin A DM9C8NX Solid tumour/cancer 2A00-2F9Z Investigative [155]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Affected By Cholinesterase (BCHE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [156]
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [157]
Galantamine DMEO794 Alzheimer disease 8A20 Approved [158]
Rivastigmine DMG629M Alzheimer disease 8A20 Approved [159]
Donepezil DMIYG7Z Advanced cancer 2A00-2F9Z Approved [160]
Succinylcholine DM2ET1M Plasma cell myeloma 2A83.1 Approved [161]
Ethopropazine DM0N3L7 Parkinson disease 8A00.0 Approved [157]
Dimenhydrinate DM264B3 Meniere disease AB31.0 Approved [162]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [163]
Chlorpheniramine DM5URA2 Allergic rhinitis CA08.0 Approved [162]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 22 member 16 (SLC22A16)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [34]
Folic Acid DMEMBJC Colorectal carcinoma Approved [164]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [165]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [166]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [154]
Drug(s) Affected By Solute carrier family 22 member 3 (SLC22A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epinephrine DM3KJBC Acute asthma CA23 Approved [167]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [167]
Norepinephrine DMOUC09 Alopecia ED70 Approved [167]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [168]
Quercetin DM3NC4M Obesity 5B81 Approved [169]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [143]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [133]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [144]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [170]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [171]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aquaporin-1 (AQP1) TTSF1KH AQP1_HUMAN Inhibitor [2]
Calcium-activated potassium channel KCa2.1 (KCNN1) TT9R6BE KCNN1_HUMAN Blocker (channel blocker) [3]
Calcium-activated potassium channel KCa2.2 (KCNN2) TT2T5M0 KCNN2_HUMAN Blocker (channel blocker) [3]
Calcium-activated potassium channel KCa2.3 (KCNN3) TT9JH25 KCNN3_HUMAN Blocker (channel blocker) [3]
Calcium-activated potassium channel KCa4.1 (KCNT1) TTGJFK1 KCNT1_HUMAN Blocker (channel blocker) [4]
Calcium-activated potassium channel KCa4.2 (KCNT2) TTLU5FO KCNT2_HUMAN Blocker (channel blocker) [5]
Calcium-activated potassium channel KCa5.1 (KCNU1) TTI9XK6 KCNU1_HUMAN Blocker (channel blocker) [6]
Charybdotoxin receptor beta-4 (BKbeta4) TT1AQ50 KCMB4_HUMAN Inhibitor [7]
Inward rectifier potassium channel Kir2.3 (KCNJ4) TTXF0ZW KCNJ4_HUMAN Blocker (channel blocker) [8]
Multidrug and toxin extrusion protein 2 (MATE2) TT7HXSL S47A2_HUMAN Modulator [9]
Solute carrier family 47 member 1 (SLC47A1) TTMHCGA S47A1_HUMAN Modulator [10]
Transient receptor potential cation channel V2 (TRPV2) TTBECWA TRPV2_HUMAN Blocker (channel blocker) [11]
Voltage-gated potassium channel Kv1.1 (KCNA1) TTS3DIK KCNA1_HUMAN Blocker (channel blocker) [12]
Voltage-gated potassium channel Kv1.2 (KCNA2) TTVFB0O KCNA2_HUMAN Blocker (channel blocker) [12]
Voltage-gated potassium channel Kv1.3 (KCNA3) TTY3UE6 KCNA3_HUMAN Blocker (channel blocker) [12]
Voltage-gated potassium channel Kv1.5 (KCNA5) TTW0CMT KCNA5_HUMAN Blocker (channel blocker) [12]
Voltage-gated potassium channel Kv1.6 (KCNA6) TTJ2W69 KCNA6_HUMAN Blocker (channel blocker) [13]
Voltage-gated potassium channel Kv1.7 (KCNA7) TTCVBT7 KCNA7_HUMAN Blocker (channel blocker) [14]
Voltage-gated potassium channel Kv1.8 (KCNA10) TTT4Y0X KCA10_HUMAN Blocker (channel blocker) [15]
Voltage-gated potassium channel Kv2.1 (KCNB1) TT5OEKU KCNB1_HUMAN Blocker (channel blocker) [16]
Voltage-gated potassium channel Kv2.2 (KCNB2) TT5PFNG KCNB2_HUMAN Blocker (channel blocker) [17]
Voltage-gated potassium channel Kv3.1 (KCNC1) TTVUWHQ KCNC1_HUMAN Blocker (channel blocker) [12]
Voltage-gated potassium channel Kv3.2 (KCNC2) TTGK3ZO KCNC2_HUMAN Blocker (channel blocker) [18]
Voltage-gated potassium channel Kv3.3 (KCNC3) TTALSY9 KCNC3_HUMAN Blocker (channel blocker) [19]
Voltage-gated potassium channel Kv3.4 (KCNC4) TTODZF1 KCNC4_HUMAN Blocker (channel blocker) [20]
Voltage-gated potassium channel Kv4.1 (KCND1) TT4DI0J KCND1_HUMAN Blocker (channel blocker) [21]
Voltage-gated potassium channel Kv7.2 (KCNQ2) TTPXI3S KCNQ2_HUMAN Blocker (channel blocker) [22]
Voltage-gated potassium channel Kv7.3 (KCNQ3) TTIVDM3 KCNQ3_HUMAN Blocker (channel blocker) [23]
Voltage-gated potassium channel Kv7.4 (KCNQ4) TT8HGRW KCNQ4_HUMAN Blocker (channel blocker) [24]
Voltage-gated potassium channel Kv7.5 (KCNQ5) TTWVL5Q KCNQ5_HUMAN Blocker (channel blocker) [25]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation/carnitine transporter 1 (SLC22A4) DT2EG60 S22A4_HUMAN Substrate [26]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [27]
Multidrug and toxin extrusion protein 2 (SLC47A2) DT3TX4H S47A2_HUMAN Substrate [28]
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [29]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [30]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Gene/Protein Processing [31]
Multidrug and toxin extrusion protein 1 (SLC47A1) OTZX0U5Q S47A1_HUMAN Regulation of Drug Effects [32]
Potassium voltage-gated channel subfamily A member 1 (KCNA1) OTP3CCEH KCNA1_HUMAN Protein Interaction/Cellular Processes [33]
Solute carrier family 22 member 16 (SLC22A16) OTG192UT S22AG_HUMAN Regulation of Drug Effects [34]
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Regulation of Drug Effects [35]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Regulation of Drug Effects [36]
Solute carrier family 22 member 4 (SLC22A4) OT4LOVI9 S22A4_HUMAN Regulation of Drug Effects [37]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4575).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 688).
3 Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
4 For K+ channels, Na+ is the new Ca2+. Trends Neurosci. 2005 Aug;28(8):422-8.
5 Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68.
6 Block of mouse Slo1 and Slo3 K+ channels by CTX, IbTX, TEA, 4-AP and quinidine. Channels (Austin). 2010 Jan-Feb;4(1):22-41.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 380).
8 Cloning and expression of a novel human brain inward rectifier potassium channel. J Biol Chem. 1994 Aug 12;269(32):20468-74.
9 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
10 Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701.
11 Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68.
12 Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
13 Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family. EMBO J. 1990 Jun;9(6):1749-56.
14 Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet. 2002 Jan;10(1):36-43.
15 KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels. Am J Physiol Renal Physiol. 2000 Jun;278(6):F1013-21.
16 Modulation of Kv2.1 channel gating and TEA sensitivity by distinct domains of SNAP-25. Biochem J. 2006 Jun 1;396(2):363-9.
17 Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles. Am J Physiol. 1998 May;274(5 Pt 1):G901-11.
18 Gating, modulation and subunit composition of voltage-gated K(+) channels in dendritic inhibitory interneurones of rat hippocampus. J Physiol. 2002 Jan 15;538(Pt 2):405-19.
19 Cloning of ShIII (Shaw-like) cDNAs encoding a novel high-voltage-activating, TEA-sensitive, type-A K+ channel. Proc Biol Sci. 1992 Apr 22;248(1321):9-18.
20 Characterization of a Shaw-related potassium channel family in rat brain. EMBO J. 1992 Jul;11(7):2473-86.
21 Endogenous Kv channels in human embryonic kidney (HEK-293) cells. Mol Cell Biochem. 2002 Sep;238(1-2):69-79.
22 Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000 Sep;58(3):591-600.
23 Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5.
24 Homomeric and heteromeric assembly of KCNQ (Kv7) K+ channels assayed by total internal reflection fluorescence/fluorescence resonance energy transfer and patch clamp analysis. J Biol Chem. 2008 Nov 7;283(45):30668-76.
25 KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000 Aug 4;275(31):24089-95.
26 Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
27 Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos. 2009 Sep;37(9):1856-63.
28 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
29 A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8.
30 Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
31 The mechanism and benefit of human butyrylcholinesterase activation by what would otherwise be inhibitors. Chem Biol Interact. 2019 Aug 1;308:350-356.
32 Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 2009 Apr;9(2):127-36.
33 Variability of Potassium Channel Blockers in Mesobuthus eupeus Scorpion Venom with Focus on Kv1.1: AN INTEGRATED TRANSCRIPTOMIC AND PROTEOMIC STUDY. J Biol Chem. 2015 May 8;290(19):12195-209. doi: 10.1074/jbc.M115.637611. Epub 2015 Mar 19.
34 Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun. 2005 Aug 5;333(3):754-62. doi: 10.1016/j.bbrc.2005.05.174.
35 Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos. 2007 Apr;35(4):667-75. doi: 10.1124/dmd.106.013581. Epub 2007 Jan 12.
36 Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58.
37 Functional and molecular effects of mercury compounds on the human OCTN1 cation transporter: C50 and C136 are the targets for potent inhibition. Toxicol Sci. 2015 Mar;144(1):105-13. doi: 10.1093/toxsci/kfu259. Epub 2014 Dec 8.
38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 385).
39 Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83.
40 SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34.
41 Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57.
42 Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol. 2007 Jul;151(5):655-65.
43 Susceptibility of cloned K+ channels to reactive oxygen species. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11796-800.
44 Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9.
45 The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines. Br J Pharmacol. 2000 Feb;129(4):627-30.
46 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
48 Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
50 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
51 Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
52 DOI: 10.1161/01.CIR.94.3.562
53 Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.
54 Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995 Jan;47(1):198-205.
55 1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers. Mol Pharmacol. 2006 Mar;69(3):718-26.
56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 387).
57 Clinical pipeline report, company report or official report of MeiraGTx.
58 Identification of novel and selective Kv2 channel inhibitors. Mol Pharmacol. 2011 Dec;80(6):959-64.
59 Novel neuroprotective K+ channel inhibitor identified by high-throughput screening in yeast. Mol Pharmacol. 2004 Jan;65(1):214-9.
60 Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology. 2001 Sep;41(4):443-53.
61 The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12.
62 The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40.
63 New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
64 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
65 Voltage-gated Potassium Channels as Therapeutic Drug Targets
66 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
67 Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
68 The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77.
69 Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005 Oct 26;25(43):9825-35.
70 KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol. 2001 Apr;280(4):C859-66.
71 Identification of novel KCNQ4 openers by a high-throughput fluorescence-based thallium flux assay. Anal Biochem. 2011 Nov 1;418(1):66-72.
72 Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS Chem Neurosci. 2011 Oct 19;2(10):572-577.
73 Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance ... J Pharmacol Exp Ther. 2005 May;313(2):840-7.
74 BK channel activation by NS-1619 is partially mediated by intracellular Ca2+ release in smooth muscle cells of porcine coronary artery
75 Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31.
76 Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology. 1996;35(7):963-8.
77 Slotoxin, alphaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes. FEBS Lett. 2001 Sep 21;505(3):369-73.
78 KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998 Dec 4;282(5395):1890-3.
79 Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58. Br J Pharmacol. 2013 Feb;168(4):1030-42.
80 The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett. 2009 Nov 13;465(2):138-42.
81 Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem. 2010 Sep 3;285(36):28322-32.
82 Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653.
83 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
84 Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56.
85 Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70.
86 Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1161-4.
87 Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry. 1999 Apr 20;38(16):4922-30.
88 Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51.
89 Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun;65(6):1364-74.
90 Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83.
91 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 386).
92 Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta. 2009 Mar;1793(3):528-39.
93 Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One. 2008 May 7;3(5):e2082.
94 TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008 Jun 11;28(24):6231-8.
95 Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7. J Biol Chem. 1998 Mar6;273(10):5851-7.
96 Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol. 2000 Jul 28;401(1):1-7.
97 Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds. J Pharmacol Exp Ther. 2001 Mar;296(3):683-9.
98 Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing properties of ... J Biol Chem. 2005 Dec 16;280(50):41404-11.
99 Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem. 2001 Apr 13;276(15):12249-56.
100 SK2 encodes the apamin-sensitive Ca(2+)-activated K(+) channels in the human leukemic T cell line, Jurkat. FEBS Lett. 2000 Mar 10;469(2-3):196-202.
101 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
102 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
103 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
104 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
105 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
106 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
107 The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
108 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
109 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
110 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
111 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
112 Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
113 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
114 FDA Drug Development and Drug Interactions
115 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
116 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
117 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
118 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
119 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
120 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
121 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
122 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
123 Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
124 OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
125 Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24.
126 Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.
127 Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
128 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
129 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
130 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
131 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
132 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
133 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
134 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
135 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
136 CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
137 Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
138 Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121. doi: 10.1016/j.toxlet.2019.12.012. Epub 2019 Dec 9.
139 Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol. 2012 Jul;50(7):2289-93. doi: 10.1016/j.fct.2012.03.077. Epub 2012 Apr 16.
140 Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
141 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
142 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
143 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
144 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
145 Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. Chem Biol Interact. 2020 Jun 1;324:109097. doi: 10.1016/j.cbi.2020.109097. Epub 2020 Apr 16.
146 Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 2006 Nov;34(11):1868-74. doi: 10.1124/dmd.106.010876. Epub 2006 Aug 23.
147 Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
148 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
149 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
150 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
151 Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
152 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
153 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
154 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
155 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
156 Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
157 Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
158 Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
159 Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
160 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
161 Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
162 Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
163 Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.
164 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
165 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
166 BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2843-52.
167 Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
168 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
169 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
170 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
171 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.